Pipex Pharmaceuticals makes appointment
This article was originally published in Scrip
Pipex Pharmaceuticals (US) has announced that Nicholas Stergis, co-founder and vice-chairman, has become chief executive officer. He succeeds Steve Kanzer, who will continue to serve as Pipex's chairman. Daniel Dorman, a director of the company, and president Charles Bisgaier, have resigned. Pipex is speciality company developing late-stage drug candidates for the treatment of central nervous system and autoimmune diseases.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.